Dalacin vaginal suppositories 3 pcs with applicator — Made in USA — Free Delivery

Use during pregnancy or lactation

Reproductive toxicity has been demonstrated in animal studies.

Application during the first trimester of pregnancy is not recommended, as there are no well-controlled studies on the use of the preparation in pregnant women during this period.

According to clinical studies of the use of the preparation Dalacin in a dosage form for vaginal use in women during the II trimester of pregnancy and the systemic use of clindamycin phosphate during the II and III trimesters did not lead to the development of congenital anomalies.

Dalacin can be used in the II and III trimester of pregnancy only if absolutely necessary. During pregnancy, it is recommended to administer vaginal suppositories without using an applicator.

Breastfeeding.

It is not known whether Dalacin penetrates into breast milk after vaginal administration. However, the appearance of clindamycin in breast milk has been reported after oral or parenteral administration. Consideration should be given to stopping breastfeeding or interrupting / refraining from therapy with Dalacin, given the benefits of breastfeeding for the baby and the benefits of treatment for the mother.

In animal studies, there was no effect on fertility.

The safety and efficacy of using the preparation Dalacin in the form of vaginal suppositories in children has not been established.

The ability to influence the reaction rate when driving or driving other mechanisms

The effect of Dalacin on the ability to drive vehicles or work with other mechanisms is absent or insignificant.

active substance: clindamycin;

1 suppository contains clindamycin phosphate in an amount equivalent to 100 mg of clindamycin;

excipients: solid fat.

Store in its original packaging at a temperature not exceeding 25 ° C out of the reach of children.

Shelf life is 3 years.